In conclusion, COPD is a global disease, with increasing prevalence and health-related impact. The loss of FEV 1 may be slowing down, but what is really needed is an intervention that improves it in ...

The final session of the symposium, "Impact on Chest Wall and Respiratory Muscles," was presented by Professor Peter T. Macklem, of the Meakins-Christie Labs at McGill University Health Center in ...

Paraseptal emphysema (PSE) is a type of pulmonary emphysema. In PSE, the outermost parts of the lungs fill with enlarged air spaces. This can cause breathing difficulties and other respiratory ...

Chronic obstructive pulmonary disease (COPD) is a heterogeneous chronic lung disease that is characterized by persistent airflow limitation and respiratory symptoms 1,2,3. At present, there is a ...

Lung cancer is among the most common cancers worldwide. In the United States and other industrialized countries, it’s the major cause of cancer mortality. Emphysema is a term that describes structural ...

Chronic obstructive pulmonary disease (COPD) is an inflammatory disorder of the lungs that affects about 10% of the adult population and is currently the third leading global cause of death. COPD is ...

Obstructive pulmonary disease is a collective term for refractory respiratory diseases with chronic airway inflammation and excessive mucus retention that are accompanied by airway obstruction. They ...

Elevated sputum azurocidin-1 levels correlate with worsening lung function and increased exacerbation frequency in patients with bronchiectasis.

Early signs of emphysema may be subtle, including shortness of breath during physical activity, a mild cough, and slight fatigue, so it’s important to pay attention to any changes in your breathing or ...

Pegtarazimod holds promise for effectively treating acute exacerbations of COPD, a major unmet need in COPD treatment.